Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715156 | 0.89 | SMO (0.52) | TSHRL3MBTL1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3713826 | 0.89 | SMO (0.52) | TSHRL3MBTL1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3715207 | 0.87 | TSHR (0.56) | TSHRLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL7886059 | 0.86 | SMO (0.54) | TSHRL3MBTL1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3713815 | 0.86 | SMO (0.54) | TSHRL3MBTL1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3709524 | 0.86 | PDK2 (0.49) | TSHRL3MBTL1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3714114 | 0.86 | PDK2 (0.49) | TSHRL3MBTL1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13373122 | 0.81 | TSHR (0.50) | TSHRLMNAGAAALDH1A1KMT2A | |
| SCHEMBL18410747 | 0.79 | LMNA (0.89) | TSHRL3MBTL1LMNAGAAALDH1A1 | |
| SCHEMBL7894275 | 0.79 | AKR1C3 (0.49) | L3MBTL1GAAALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170234881-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170234881-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-17 | — | — | US | disclosed |
| WO-2016034742-A1 | METHODS OF DIAGNOSING AND TREATING CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-03-10 | — | — | WO | disclosed |
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138190-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | AMGEN INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | AMGEN INC. | 2009-07-09 | — | — | US | disclosed |
| US-7524848-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524848-B2 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176768-A1 | DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES | GPR119, GLP1R, INSR | TSHR 299/4885L3MBTL1 1927/4885CYP3A4 888/4885 |
| US-20070249626-A1 | Diaza heterocyclic amide compounds and their uses | GPR119, GLP1R, INSR | TSHR 299/4885L3MBTL1 1927/4885CYP3A4 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.